

**Agenda**  
**Genetics Advisory Committee to the Oregon Health Services Commission and**  
**Division of Medical Assistance Programs**

September 22, 2010 Meeting

Clackamas Community College Wilsonville Training Center, Room 211

29353 SW Town Center Loop E, Wilsonville, OR, 97070

1:00 – 3:00 pm

1. Introductions
2. Purpose for convening the group
  - a. Committee Background Information (Tab #1)
3. Overview of current DMAP Genetic Testing Guidelines and Algorithm
  - a. DMAP Genetic Testing Guidelines (Tab #2)
  - b. Botkin et al - Outcomes of interest in evidence-based evaluations of genetic tests (Tab #3)
4. What changes if any should be made to the current specific guidelines for developmental delay in children? Specifically, should microarray technologies be covered?
  - a. Summary for Mental Retardation (Tab #4)
  - b. Manning et al – 2010 American College of Medical Genetics Practice Guideline (Tab #5)
  - c. Miller et al – 2010 Consensus statement from The International Standard Cytogenomic Array (ISCA) Consortium (Tab #6)
  - d. Shevell et al – 2003 Practice Parameter from the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society (Tab #7)
  - e. Moeschler & Shevell – 2006 guideline from the American Academy of Pediatrics (Tab #8)
5. Should genetic testing for MODY be covered?
  - a. Summary for MODY (Tab #9)
6. Should genetic testing for neurofibromatosis be covered?
  - a. Summary for Neurofibromatosis (Tab #10)
7. Identify topics for the next meeting
  - a. Other new generations of genetic tests and how they fit into the algorithm
  - b. Oncogenes
  - c. Plavix
8. Identify work to be completed before the next meeting

**Reference Documents**

- Tab #3 Botkin JR, Teutsch SM, Kaye CI, Hayes M, Haddow JE, Bradley LA, Szegda K, Dotson WD; EGAPP Working Group. Outcomes of interest in evidence-based evaluations of genetic tests. *Genet Med.* 2010 Apr;12(4):228-35.

- Tab #5 Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med*. E-Publication, published before print. Update of 2007 Sep;9(9):650-3.
- Tab #6 Miller DT, Adam MP, Aradhya S, Biesecker LG, et al, Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies. *The American Journal of Human Genetics* 86, 749–764, 2010.
- Tab #7 Shevell M, Ashwal S, Donley D, Flint J et al. Quality Standards Subcommittee of the American Academy of Neurology; Practice Committee of the Child Neurology Society. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. *Neurology*. 2003 Feb 11;60(3):367-80.
- Tab #8 Moeschler JB, Shevell M; American Academy of Pediatrics Committee on Genetics. Clinical genetic evaluation of the child with mental retardation or developmental delays. *Pediatrics*. 2006 Jun;117(6):2304-16.